查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1847862

2025-2032 年全球荷尔蒙避孕市场预测（按药丸类型、荷尔蒙成分、销售管道和最终用户划分）

Hormonal Contraceptives Market by Contraceptive Type, Hormonal Composition, Sales Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，荷尔蒙避孕市场将成长至 314.4 亿美元，复合年增长率为 6.96%。

主要市场统计数据
基准年2024年 183.4亿美元
预计2025年 196.4亿美元
预测年份：2032年 314.4亿美元
复合年增长率（%） 6.96%

将影响荷尔蒙避孕前景的临床、监管和获取主导因素具体化，以指导经营团队决策和策略重点

本介绍旨在为高层相关人员提供临床创新、使用者偏好、监管发展和供应链复杂性的综合观点，概述当前的荷尔蒙避孕药市场格局。长效可逆避孕药的进步，以及对避孕选择和可及性的重新重视，重塑了临床路径和采购重点。同时，不断变化的报销政策和不断发展的监管指南正在改变增量产品和新产品的核准时间表和销售管道。

因此，领导者不仅要考虑产品属性，还要考虑影响采用的更广泛的生态系统，包括供应商教育、用户参与的数位管道以及分销弹性。本摘要综合了跨职能讯号，以阐明临床有效性、以患者为中心的设计和营运准备度之间的交汇点。透过将策略重点与这些系统性趋势结合，组织可以更好地预测采用障碍，优化商业化顺序，并加强与相关人员的伙伴关係，从而支持避孕药具的永续成长。

配方、给药系统、数位化照护途径以及公平主导的政策转变的进步如何重塑避孕药具的供应和采用趋势

荷尔蒙避孕领域的变革性变化反映了配方、给药方式和服务模式的整合创新，这些创新正在改变避孕服务的取得和提供方式。随着医疗服务提供者寻求减轻使用者负担并提高依从性，长效避孕方法正日益受到青睐，而下一代配方和新型给药平台则致力于平衡疗效和耐受性。除了产品创新之外，数位化护理途径和远端医疗处方正在扩大网路基地台并重塑患者病人历程，改变传统药房和诊所管道在启动和追踪中所扮演的角色。

此外，人们对生殖自主权和平等的日益关注，正在推动政策转变和资金变化，从而影响采购和公共卫生计画。随着製造商和经销商透过库存策略和采购多元化来应对地缘政治压力和原材料限制，供应链韧性正成为一项竞争优势。这些动态共同创造了一个以使用者为中心、技术赋能、以供应为中心的环境，这需要快速的商业化模式以及临床、监管和商业职能部门之间更紧密的协作。

评估美国2025 年关税政策转变如何促进采购多元化、本地生产投资以及整个供应链的采购适应

美国2025年关税的实施对避孕用品供应链、采购惯例和商业性优先顺序产生了多方面的影响。关税主导的成本压力促使製造商和经销商重新评估筹资策略，加快推进某些製造流程的本地化，实现供应商多元化，并重新协商供应商合同，以在不影响产品品质的情况下保护净利率。因此，一些公司优先投资区域产能和双边供应商关係，以降低贸易政策波动对其的影响。

此外，采购机构和机构买家已透过修改采购週期和库存缓衝来应对价格不确定性。这影响了供应商和大型采购商之间的谈判动态，更重视整体拥有成本、合约价格稳定性和供应安全。监管机构也观察到，成本调整会对报销谈判和竞标连锁反应，从而产生行政影响。虽然关税是影响商业性选择的众多因素之一，但它也成为营运弹性策略和加速本地化考虑的催化剂，并可能在可预见的未来影响采购蓝图和供应商选择。

与避孕类型、荷尔蒙成分、分销管道和最终用户偏好相关的详细主导观点，有助于确定优先顺序和商业化

细分洞察揭示了产品属性、荷尔蒙成分、分销管道和最终用户偏好在何处交叉以影响采用和程序设计。根据避孕类型，有植入、注射、避孕器、口服避孕药、经皮吸收贴片和避孕环。对于植入，双桿和单桿设计之间的差异在于插入工作流程和提供者训练要求。对于注射剂，有Medroxyprogesterone孕酮和庚酸炔诺酮製剂，它们的给药间隔和给药时间表各不相同。口服避孕药分为复方口服避孕药及仅含黄体素的药片，需考虑处方。对于避孕环，有延长使用和每月环选项，它们的依从性和咨询含义各不相同。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 缩短月经週期的长效口服避孕药的需求不断增加
  • 整合荷尔蒙追踪和避孕依从性支持的数位疗法的成长
  • 越来越多地采用可生物降解的皮下植入系统，该系统可在数年内释放激素
  • 为了尽量减少副作用，对开立微剂量避孕药的监管审查已经加强。
  • 基于个体荷尔蒙代谢的经皮避孕贴片客製化浪潮
  • 扩大男性荷尔蒙避孕试验，探索雄性激素抑制的可逆避孕方法
  • 整合远端医疗服务，实现荷尔蒙避孕药的远距处方和监测
  • 研发长效注射药物，减少给药频率，提高依从性

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 荷尔蒙避孕市场（依避孕方法类型）

  • 植入
    • 双桿植入
    • 单桿植入
  • 注射避孕药
    • 长效Medroxyprogesterone醋酸盐
    • 庚酸炔诺酮
  • 子宫内避孕器
  • 口服避孕药
    • 复方口服避孕药
    • 仅含黄体素的药丸
  • 经皮吸收贴片
  • 避孕环
    • 长期使用环
    • 月环

9. 荷尔蒙避孕市场（依荷尔蒙成分划分）

  • 复方荷尔蒙避孕药
  • 仅含黄体素的避孕药

第 10 章 荷尔蒙避孕市场（依销售管道）

  • 医院药房
  • 网路药局
  • 零售药局

第 11 章 荷尔蒙避孕药市场（依最终用户）

  • 诊所
    • 私人诊所
    • 公立诊所
  • 家庭医疗保健
  • 医院

第十二章荷尔蒙避孕市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 荷尔蒙避孕药市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 荷尔蒙避孕药市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Bayer AG
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Allergan plc
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Gedeon Richter plc
    • Sun Pharmaceutical Industries Ltd.
    • Cipla Limited
Product Code: MRR-4103B31E0668

The Hormonal Contraceptives Market is projected to grow by USD 31.44 billion at a CAGR of 6.96% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 18.34 billion
Estimated Year [2025] USD 19.64 billion
Forecast Year [2032] USD 31.44 billion
CAGR (%) 6.96%

Contextualizing clinical, regulatory, and access-driven forces shaping the hormonal contraceptives landscape to guide executive decision-making and strategic priorities

The introduction frames the current hormonal contraceptives landscape by situating clinical innovation, user preferences, regulatory dynamics, and supply chain complexity within an integrated perspective tailored for senior stakeholders. Advances in long-acting reversible contraceptives alongside renewed emphasis on contraceptive choice and access have reshaped clinical pathways and procurement priorities. At the same time, shifting reimbursement policies and evolving guidance from regulatory authorities have altered approval timelines and commercial pathways for both incremental and novel products.

Consequently, leaders must consider not only product attributes but also the broader ecosystem that governs adoption, including provider education, digital channels for user engagement, and distribution resilience. This summary synthesizes cross-functional signals to clarify where clinical efficacy, patient-centered design, and operational readiness intersect. By aligning strategic priorities with these systemic trends, organizations can better anticipate adoption hurdles, optimize commercialization sequencing, and strengthen stakeholder partnerships that underpin sustainable growth in contraceptive provision.

How advancements in formulations, delivery systems, digital care pathways, and equity-driven policy shifts are collectively reshaping contraceptive provision and adoption trends

Transformative shifts in the hormonal contraceptives landscape reflect converging innovations in formulation, delivery, and service models that are changing how contraceptive care is accessed and delivered. Long-acting methods have gained traction as providers seek to reduce user burden and increase adherence, while next-generation formulations and novel delivery platforms seek to balance efficacy with tolerability. Parallel to product innovation, digitization of care pathways and telehealth-enabled prescribing have expanded points of access, reshaping patient journeys and altering the role that traditional pharmacy and clinic channels play in initiation and follow-up.

In addition, heightened attention to reproductive autonomy and equity has prompted policy shifts and funding reallocations that influence procurement and public health programming. Supply chain resilience has become a competitive differentiator, as manufacturers and distributors respond to geopolitical pressures and raw material constraints with inventory strategies and diversified sourcing. Taken together, these dynamics are producing a more user-centric, technology-enabled, and supply-conscious environment that requires nimble commercialization models and closer collaboration across clinical, regulatory, and commercial functions.

Assessing how 2025 tariff policy shifts in the United States catalyzed sourcing diversification, regional production investments, and procurement adaptations across supply chains

The introduction of tariffs in the United States in 2025 has had a multi-dimensional influence on the contraceptive supply chain, procurement practices, and commercial prioritization. Tariff-driven cost pressures have prompted manufacturers and distributors to reassess sourcing strategies, accelerating efforts to localize certain manufacturing steps, diversify supplier bases, and renegotiate supplier contracts to preserve margins without compromising product quality. As a result, some firms have prioritized investments in regional production capacity and bi-lateral supplier relationships to mitigate exposure to trade policy volatility.

Moreover, procurement entities and institutional buyers have adapted by revising purchasing cycles and inventory buffers to manage pricing uncertainty. This has impacted negotiation dynamics between suppliers and large purchasers, with increased emphasis on total cost of ownership, contracted price stability, and supply guarantees. Regulatory teams have also observed administrative effects as cost adjustments ripple through reimbursement discussions and tenders. While tariffs are one factor among many shaping commercial choices, they have acted as a catalyst for operational resilience strategies and accelerated localization considerations that will influence sourcing roadmaps and supplier selection for the foreseeable future.

Detailed segmentation-driven perspectives linking contraceptive type, hormonal composition, distribution channels, and end-user settings to inform prioritization and commercialization

Segmentation insights reveal where product attributes, hormonal composition, distribution channels, and end-user settings intersect to shape adoption and program design. Based on contraceptive type, the landscape includes implants, injectable contraceptives, intrauterine devices, oral contraceptives, transdermal patches, and vaginal rings; within implants, distinctions between double-rod and single-rod designs drive different insertion workflows and provider training needs, while injectable contraceptives divide into depot medroxyprogesterone acetate and norethisterone enanthate formulations that differ in dosing intervals and administration settings. Oral contraceptives bifurcate into combined oral contraceptives and progestin-only pills with distinct prescribing considerations, and vaginal rings are differentiated by extended-use and monthly ring options that carry divergent adherence and counseling implications.

Based on hormonal composition, the field separates into combined hormonal contraceptives and progestin-only contraceptives, a partition that matters clinically for contraindications, side-effect profiles, and patient selection. When viewed through the lens of sales channel, hospital pharmacies, online pharmacies, and retail pharmacies each present unique distribution economics, compliance requirements, and opportunities for digital engagement. Finally, based on end user, clinics, home healthcare, and hospitals represent varied points of care; clinics themselves divide into private and public clinics, creating distinct procurement pathways and payer interactions. Together, these segment dimensions inform product development priorities, clinical training investments, and channel strategies that align with both user preferences and provider workflows.

Examining how regional regulatory diversity, procurement models, and digital adoption across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated strategic responses

Regional dynamics demonstrate differentiated demand drivers, regulatory frameworks, and distribution challenges that shape strategic priorities across geographies. In the Americas, payer structures, public health programs, and private provider networks interact to influence uptake patterns and procurement models, with particular attention to reproductive health policy shifts that affect access and funding flows. The Europe, Middle East & Africa region presents a heterogeneous regulatory mosaic, where regulatory harmonization efforts coexist with varied reimbursement landscapes and infrastructure constraints that influence product selection and implementation strategies. In Asia-Pacific, rapid urbanization, digital health adoption, and manufacturing capacity expansion have created both commercial opportunities and operational complexities, as firms navigate diverse regulatory expectations and local market entry requirements.

Consequently, regional strategies must balance global product platforms with tailored approaches to distribution, pricing, and provider engagement. Cross-border logistics considerations and regional manufacturing investments have become increasingly relevant to maintain continuity of supply and competitive positioning. By mapping clinical, regulatory, and commercial levers region by region, organizations can prioritize investments that align with local access priorities while leveraging scale where regulatory convergence or manufacturing synergies exist.

How product differentiation, partnership strategies, and operational resilience define competitive positioning among established and emerging contraceptive innovators

Competitive insights highlight how established pharmaceutical firms and emerging specialists are responding across product innovation, supply chain resilience, and go-to-market strategies. Leading companies are investing in formulation improvements and differentiated delivery mechanisms to address tolerability and adherence, while newer entrants and niche players focus on specialized platforms such as extended-duration rings or next-generation subdermal devices. Partnerships and licensing arrangements have become tactical levers to accelerate time-to-clinic and broaden product portfolios without bearing the full cost of development.

Operationally, firms are strengthening supplier diversification and pursuing regional manufacturing or contract manufacturing arrangements to reduce exposure to trade disruptions. Commercially, there is an increased emphasis on provider education, digital engagement tools, and value-based contracting to demonstrate outcomes and secure formulary placement. At the same time, privacy, pharmacovigilance, and post-market surveillance have escalated in importance, prompting investments in real-world evidence generation and patient-reported outcomes programs. Together, these initiatives reflect a competitive environment where clinical differentiation, operational robustness, and evidence-driven commercialization determine sustained advantage.

Practical strategic priorities and operational measures industry leaders should adopt to align product development, distribution, and stakeholder engagement with evolving care models

Actionable recommendations for industry leaders focus on aligning product development, commercial execution, and operational systems to emergent user and policy realities. First, prioritize development pathways that reduce user burden and improve adherence, such as longer-acting formulations and intuitive delivery systems, while ensuring that clinical and safety profiles meet diverse patient needs. Second, strengthen supply chain resilience through supplier diversification, regional manufacturing options, and contractual mechanisms that provide price and volume stability under policy shifts.

Third, invest in multi-channel distribution strategies that integrate hospital pharmacies, retail and online pharmacies, and telehealth-enabled prescribing to broaden access and streamline patient journeys. Fourth, enhance provider and payer engagement through evidence packages that emphasize real-world outcomes, cost-effectiveness, and implementation support. Finally, embed equity and access objectives into product and commercial planning to address disparities in contraceptive access. Implementing these recommendations requires coordinated governance across R&D, regulatory, supply chain, and commercial functions to translate strategic intent into measurable outcomes.

Transparent mixed-methods research approach integrating primary stakeholder interviews, regulatory and clinical evidence review, and expert validation to ensure analytical rigor

The research methodology combined a mixed-methods approach to ensure depth and validity across clinical, regulatory, and commercial domains. Primary research included structured interviews with clinicians, procurement professionals, and payers to capture firsthand perspectives on prescribing behaviors, procurement constraints, and access barriers. Secondary research entailed a comprehensive review of regulatory guidance, clinical literature, and public policy statements to triangulate primary findings and provide contextual grounding.

Data synthesis emphasized cross-validation, whereby qualitative insights informed the interpretation of regulatory and operational signals, and documentary evidence corroborated recurring themes. Expert review sessions with clinical and supply chain specialists refined assumptions and clarified technical implications. Transparency was maintained regarding sources of evidence and analytical assumptions, and known limitations-such as jurisdictional heterogeneity in regulatory rules and evolving tariff landscapes-were explicitly documented to guide interpretation and application of findings.

Summarizing strategic imperatives that connect clinical innovation, distribution evolution, and supply resilience to advance access and adoption of hormonal contraceptives

In conclusion, hormonal contraceptives are situated at the intersection of clinical innovation, evolving care delivery models, and policy dynamics that together shape access and adoption. Long-acting and user-centric delivery approaches are gaining momentum, while digital channels and provider education are altering traditional distribution and counseling models. Concurrently, trade policy shifts and supply chain pressures underscore the need for resilient sourcing strategies and regional operational capacity.

Decision-makers who align product development with provider workflows, invest in diversified distribution channels, and prioritize evidence generation for real-world outcomes will be best positioned to respond to both clinical and commercial imperatives. By integrating these strategic priorities with operational safeguards and stakeholder engagement plans, organizations can more effectively support access, drive adoption, and contribute to improved reproductive health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising demand for extended-cycle oral contraceptives offering fewer menstrual periods
  • 5.2. Growth in digital therapeutics integrating hormone tracking with contraceptive adherence support
  • 5.3. Increasing adoption of biodegradable subcutaneous implant systems releasing hormones over multiple years
  • 5.4. Regulatory scrutiny intensifying around microdose contraceptive formulations to minimize side effects
  • 5.5. Surge in customization of transdermal contraceptive patches based on individual hormone metabolism
  • 5.6. Expansion of male hormonal contraceptive trials exploring androgen suppression for reversible contraception
  • 5.7. Integration of telehealth services for remote prescription and monitoring of hormone contraceptives
  • 5.8. R&D in long-acting injectable formulations targeting reduced dosing frequency and improved compliance

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hormonal Contraceptives Market, by Contraceptive Type

  • 8.1. Implants
    • 8.1.1. Double-Rod Implants
    • 8.1.2. Single-Rod Implants
  • 8.2. Injectable Contraceptives
    • 8.2.1. Depot Medroxyprogesterone Acetate
    • 8.2.2. Norethisterone Enanthate
  • 8.3. Intrauterine Devices
  • 8.4. Oral Contraceptives
    • 8.4.1. Combined Oral Contraceptives
    • 8.4.2. Progestin-Only Pills
  • 8.5. Transdermal Patches
  • 8.6. Vaginal Rings
    • 8.6.1. Extended-Use Rings
    • 8.6.2. Monthly Rings

9. Hormonal Contraceptives Market, by Hormonal Composition

  • 9.1. Combined Hormonal Contraceptives
  • 9.2. Progestin-Only Contraceptives

10. Hormonal Contraceptives Market, by Sales Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Hormonal Contraceptives Market, by End User

  • 11.1. Clinics
    • 11.1.1. Private Clinics
    • 11.1.2. Public Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals

12. Hormonal Contraceptives Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hormonal Contraceptives Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hormonal Contraceptives Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Bayer AG
    • 15.3.2. Merck & Co., Inc.
    • 15.3.3. Pfizer Inc.
    • 15.3.4. Johnson & Johnson
    • 15.3.5. Allergan plc
    • 15.3.6. Teva Pharmaceutical Industries Ltd.
    • 15.3.7. Viatris Inc.
    • 15.3.8. Gedeon Richter plc
    • 15.3.9. Sun Pharmaceutical Industries Ltd.
    • 15.3.10. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HORMONAL CONTRACEPTIVES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HORMONAL CONTRACEPTIVES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HORMONAL CONTRACEPTIVES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DOUBLE-ROD IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SINGLE-ROD IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY DEPOT MEDROXYPROGESTERONE ACETATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY NORETHISTERONE ENANTHATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY EXTENDED-USE RINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY MONTHLY RINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED HORMONAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTIN-ONLY CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PUBLIC CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST HORMONAL CONTRACEPTIVES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY CONTRACEPTIVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RINGS, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONAL COMPOSITION, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA HORMONAL CONTRACEPTIVES MARKET SIZ